TOS-358 is a covalent, pan-mutant, a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include ...

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...

MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ...

FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...

Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (CiPHeR). A phase 1 ...

As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid ...

Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

This table provides an overview of antiretroviral agents currently under development. Since these compounds are being actively researched and evaluated, the information in this table may not always be ...